BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim H, Kim H, Cho SK, Kim JB, Joung B, Kim C. Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation. Korean Circ J 2019;49:252-63. [PMID: 30468041 DOI: 10.4070/kcj.2018.0220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Azahar SN, Sulong S, Wan Zaidi WA, Muhammad N, Kamisah Y, Masbah N. Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study. IJERPH 2022;19:1078. [DOI: 10.3390/ijerph19031078] [Reference Citation Analysis]
2 Zhou H, Nie X, Jiang M, Dong W. Cost-effectiveness of anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation in mainland China. J Clin Pharm Ther 2021. [PMID: 34783090 DOI: 10.1111/jcpt.13575] [Reference Citation Analysis]
3 Choi JH, Kim W, Kim YT, Cho J, Shin SY, Kim C, Kim J. Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk. Front Cardiovasc Med 2022;9:849474. [DOI: 10.3389/fcvm.2022.849474] [Reference Citation Analysis]
4 Cho IY. Using non-vitamin K oral anticoagulants in specific patient populations: a study of Korean cases. Ther Clin Risk Manag 2019;15:1183-206. [PMID: 31632045 DOI: 10.2147/TCRM.S204377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kim M, Kim W, Kim C, Joung B. Cost-Effectiveness of Rate- and Rhythm-Control Drugs for Treating Atrial Fibrillation in Korea. Yonsei Med J 2019;60:1157-63. [PMID: 31769246 DOI: 10.3349/ymj.2019.60.12.1157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Park J, Lee SR, Choi EK, Kwon S, Jung JH, Han KD, Cha MJ, Ko SB, Oh S, Lip GYH. Effectiveness and Safety of Direct Oral Anticoagulant for Secondary Prevention in Asians with Atrial Fibrillation. J Clin Med 2019;8:E2228. [PMID: 31861095 DOI: 10.3390/jcm8122228] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
7 Wei H, Cui C, Cui X, Liu Y, Li D. Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China. BMC Health Serv Res 2021;21:96. [PMID: 33509171 DOI: 10.1186/s12913-021-06084-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Noviyani R, Youngkong S, Nathisuwan S, Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, McKay G, Sritara P, Attia J, Thakkinstian A. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evid Based Med 2021:bmjebm-2020-111634. [PMID: 34635480 DOI: 10.1136/bmjebm-2020-111634] [Reference Citation Analysis]